Skip to content

Trial Summary

This is a Phase 1 trial to evaluate the safety, pharmacokinetics and efficacy of TG-1701, a Bruton’s Tyrosine Kinase (BTK) inhibitor in patients with relapsed or refractory B-cell malignancies.

Acronym:

TG-1701-101

ACTRN/NCT /ethics:

NCT03671590

Scientific title:

Study of TG-1701, an irreversible Bruton’s Tyrosine Kinase inhibitor, in patients with B-cell malignancies

Sponsor / Cooperative group:

TG Therapeutics Inc.

Trial & Patient Characteristics

Cancer TypeLymphoma
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
SexBoth
Tumour Stream Lymphoma
Cancer StageLocally Recurrent or Locally Advanced
Anticipated Start Date2018-09-10
Anticipated End Date2020-09-01

Participating Hospitals

HospitalAshford Cancer Centre Research
Clinical Trial CoordinatorSue Yeend
Emailsyeend@adelaidecancercentre.com.au
Phone08 8292 2240
Principal InvestigatorDr Stanley Cheung
Recruitment StatusRecruiting